As part of our on-going effort to develop (64)Cu-based radiopharmaceuticals for PET (positron emission tomography) imaging of multidrug resistance in cancer, we prepared a tetramethylfuranone-functionalized diiminedioxime ligand, TMFPreH (TMFPreH = 4-[3-(4-Hydroxyimino-2,2,5,5-dimethyl-dihydro-furan-3-ylideneamino)-propylimino]-2,2,5,5-tetramethyl-dihydro-furan-3-one oxime) and its Cu(II) and Ni(II) complexes. When the copper(II) complex was prepared from Cu(ClO(4))(2) in ethanol, it was isolated as a Cu(II)-bridged dimer, but when it was prepared from Cu(OAc)(2) and heated in acetone, an unusual example of an acetone adduct of the ligand is formed by reduction of one of the imine double bonds by the solvent. The Ni(II) complex is square pyramidal with the perchlorate counterion at the apex.
As part of our on-going effort to develop (64)Cu-based radiopharmaceuticals for PET (positron emission tomography) imaging of multidrug resistance inn class="Disease">cancer, we prepared a tetramethylfuranone-functionalized diiminedioxime ligand, TMFPreH (TMFPreH = 4-[3-(4-Hydroxyimino-2,2,5,5-dimethyl-dihydro-furan-3-ylideneamino)-propylimino]-2,2,5,5-tetramethyl-dihydro-furan-3-one oxime) and its Cu(II) and Ni(II) complexes. When the copper(II) complex was prepared from Cu(ClO(4))(2) in ethanol, it was isolated as a Cu(II)-bridged dimer, but when it was prepared from Cu(OAc)(2) and heated in acetone, an unusual example of an acetone adduct of the ligand is formed by reduction of one of the imine double bonds by the solvent. The Ni(II) complex is square pyramidal with the perchlorate counterion at the apex.
Authors: C L Crankshaw; M Marmion; G D Luker; V Rao; J Dahlheimer; B D Burleigh; E Webb; K F Deutsch; D Piwnica-Worms Journal: J Nucl Med Date: 1998-01 Impact factor: 10.057
Authors: C Rossetti; G Vanoli; G Paganelli; M Kwiatkowski; F Zito; F Colombo; C Bonino; A Carpinelli; R Casati; K Deutsch Journal: J Nucl Med Date: 1994-10 Impact factor: 10.057
Authors: F J Wackers; D S Berman; J Maddahi; D D Watson; G A Beller; H W Strauss; C A Boucher; M Picard; B L Holman; R Fridrich Journal: J Nucl Med Date: 1989-03 Impact factor: 10.057